Synairgen plc
OTC: SYGGF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joseph Tregonning Colliver
- Employees
- 36
- Headquarters
- Southampton, United Kingdom
- IPO year
- 2020
- Market cap
- $110.3K
- Website
- https://www.synairgen.com
Loading SYGGF…
Loading profile data…Frequently asked questions about SYGGF
What does Synairgen plc (SYGGF) do?
Synairgen plc is a biopharmaceutical company focused on the discovery and advancement of therapeutic drugs for various respiratory conditions. Their product pipeline features SNG001, an inhaled interferon beta under development for the treatment of COVID-19. They are also conducting Phase II clinical trials for an inhaled formulation of interfer...
Where does SYGGF trade?
Synairgen plc (SYGGF) trades on the Other OTC.
What sector is SYGGF in?
Synairgen plc (SYGGF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Synairgen plc?
Joseph Tregonning Colliver is the chief executive officer of Synairgen plc (SYGGF).
Where is Synairgen plc headquartered?
Synairgen plc is headquartered in United Kingdom.
Does SYGGF pay a dividend?
Synairgen plc (SYGGF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SYGGF go public?
Synairgen plc (SYGGF) completed its initial public offering in 2020.